Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease; primary trial completion expected in July 2017.
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|MRK||Community voting in process|
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?